Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip C Robinson

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2015
ERAP1 biology and assessment in Ankylosing SpondylitisPhilip C Robinson, Matthew A Brown
Australian Family Physician|May 12, 2016
The management of gout: Much has changedPhilip C Robinson, Lisa K Stamp
Arthritis Research & Therapy|August 29, 2014
The window of opportunity: a relevant concept for axial spondyloarthritisPhilip C Robinson, Matthew A Brown
The Lancet. Rheumatology|March 3, 2021
Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this?Milena A Gianfrancesco, Philip C Robinson
Current Rheumatology Reports|February 26, 2013
Classification criteria: peripheral spondyloarthropathy and psoriatic arthritisWilliam J Taylor, Philip C Robinson
Clinical Rheumatology|January 17, 2013
A qualitative and quantitative analysis of the characteristics of gout patient education resourcesPhilip C Robinson, H Ralph Schumacher
Molecular Immunology|August 7, 2013
Genetics of ankylosing spondylitisPhilip C Robinson, Matthew A Brown
The Journal of Rheumatology|February 17, 2018
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU MonitoringPhilip C Robinson, Nicola Dalbeth, Peter Donovan
Current Opinion in Rheumatology|December 15, 2021
Gout and the COVID-19 pandemicVicky Tai, Philip C Robinson, Nicola Dalbeth
The Lancet. Rheumatology|November 22, 2021
What does endemic COVID-19 mean for the future of rituximab?David F L Liew, Philip C Robinson
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2015
ERAP1 biology and assessment in Ankylosing SpondylitisPhilip C Robinson, Matthew A Brown
Australian Family Physician|May 12, 2016
The management of gout: Much has changedPhilip C Robinson, Lisa K Stamp
Arthritis Research & Therapy|August 29, 2014
The window of opportunity: a relevant concept for axial spondyloarthritisPhilip C Robinson, Matthew A Brown
The Lancet. Rheumatology|March 3, 2021
Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this?Milena A Gianfrancesco, Philip C Robinson
Current Rheumatology Reports|February 26, 2013
Classification criteria: peripheral spondyloarthropathy and psoriatic arthritisWilliam J Taylor, Philip C Robinson
Clinical Rheumatology|January 17, 2013
A qualitative and quantitative analysis of the characteristics of gout patient education resourcesPhilip C Robinson, H Ralph Schumacher
Molecular Immunology|August 7, 2013
Genetics of ankylosing spondylitisPhilip C Robinson, Matthew A Brown
The Journal of Rheumatology|February 17, 2018
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU MonitoringPhilip C Robinson, Nicola Dalbeth, Peter Donovan
Current Opinion in Rheumatology|December 15, 2021
Gout and the COVID-19 pandemicVicky Tai, Philip C Robinson, Nicola Dalbeth
The Lancet. Rheumatology|November 22, 2021
What does endemic COVID-19 mean for the future of rituximab?David F L Liew, Philip C Robinson
Pageof 15